[go: up one dir, main page]

DE60235900D1 - Osuppressivum - Google Patents

Osuppressivum

Info

Publication number
DE60235900D1
DE60235900D1 DE60235900T DE60235900T DE60235900D1 DE 60235900 D1 DE60235900 D1 DE 60235900D1 DE 60235900 T DE60235900 T DE 60235900T DE 60235900 T DE60235900 T DE 60235900T DE 60235900 D1 DE60235900 D1 DE 60235900D1
Authority
DE
Germany
Prior art keywords
present
derivatives
diaryl
osuppressivum
benzyloxyphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235900T
Other languages
English (en)
Inventor
Yasushi Kohno
Naoki Ando
Takahiro Tanase
Kazuhiko Kuriyama
Satoru Iwanami
Shinji Kudou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60235900D1 publication Critical patent/DE60235900D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Cephalosporin Compounds (AREA)
  • Fats And Perfumes (AREA)
DE60235900T 2001-09-27 2002-09-25 Osuppressivum Expired - Lifetime DE60235900D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001297400 2001-09-27
JP2002216191 2002-07-25
PCT/JP2002/009864 WO2003029184A1 (en) 2001-09-27 2002-09-25 Diaryl ether derivative, addition salt thereof, and immunosuppressant

Publications (1)

Publication Number Publication Date
DE60235900D1 true DE60235900D1 (de) 2010-05-20

Family

ID=26623110

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235900T Expired - Lifetime DE60235900D1 (de) 2001-09-27 2002-09-25 Osuppressivum

Country Status (7)

Country Link
US (1) US6963012B2 (de)
EP (1) EP1431275B1 (de)
JP (1) JP4152884B2 (de)
AT (1) ATE463478T1 (de)
CA (1) CA2460640C (de)
DE (1) DE60235900D1 (de)
WO (1) WO2003029184A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0212894B8 (pt) * 2001-09-27 2021-05-25 Kyorin Seiyaku Kk composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
EP1471054B1 (de) 2002-01-11 2009-07-01 Daiichi Sankyo Company, Limited Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
KR20120125398A (ko) 2002-05-16 2012-11-14 노파르티스 아게 암에서 edg 수용체 결합제의 용도
KR101003877B1 (ko) 2002-09-19 2010-12-30 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체와 그 부가염 및 면역 억제제
KR101095807B1 (ko) 2002-09-24 2011-12-21 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
DE602004017847D1 (de) 2003-04-08 2009-01-02 Novartis Ag Feste pharmazeutische darreichungsformen mit einem s1p rezeptoragonisten und einem zuckeralkohol
ATE547395T1 (de) * 2003-04-30 2012-03-15 Novartis Pharma Gmbh Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0324210D0 (en) 2003-10-15 2003-11-19 Novartis Ag Organic compounds
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
TW200526548A (en) * 2003-12-25 2005-08-16 Sankyo Co Ether derivatives
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물
WO2005105146A1 (en) 2004-05-03 2005-11-10 Novartis Ag Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
RU2396982C2 (ru) * 2004-07-16 2010-08-20 Киорин Фармасьютикал Ко., Лтд. Эффективный способ использования лекарственных средств и способ предотвращения выраженности побочных эффектов
TW200611687A (en) * 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
RU2402324C2 (ru) 2004-07-30 2010-10-27 Новартис Аг Композиции на основе соединений 2-амино-1,3-пропандиола
ES2563034T3 (es) 2004-10-12 2016-03-10 Kyorin Pharmaceutical Co., Ltd. Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol e hidratos del mismo, e intermedios para la producción de los mismos
ES2495690T3 (es) * 2004-11-29 2014-09-17 Novartis Ag Régimen de dosificación de un agonista del receptor S1P
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ppar調節劑之醫藥組成物的用途
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
SG165364A1 (en) * 2005-09-09 2010-10-28 Novartis Ag Treatment of autoimmune diseases
EP1932522B1 (de) * 2005-10-07 2012-05-23 Kyorin Pharmaceutical Co., Ltd. Therapeutisches Mittel gegen Lebererkrankungen mit einem 2-Amino-1,3-propandiol-Derivat als Wirkstoff
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
BRPI0710878A2 (pt) 2006-04-11 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
ES2491224T3 (es) 2006-04-28 2014-09-05 Mitsubishi Tanabe Pharma Corporation Compuesto de 2-aminobutanol y su uso para fines médicos
TW200815600A (en) 2006-08-04 2008-04-01 Daiichi Sankyo Co Ltd An enzyme for phosphorizing a medicine
JP5140593B2 (ja) 2006-08-08 2013-02-06 杏林製薬株式会社 アミノアルコール誘導体及びそれらを有効成分とする免疫抑制剤
HRP20131172T1 (hr) * 2006-08-08 2014-01-17 Kyorin Pharmaceutical Co., Ltd. Esterski derivat aminofosforne kiseline i modulator receptora s1p koji sadrži isti kao aktivni sastojak
BRPI0813683A2 (pt) * 2007-06-14 2019-09-24 Mitsubishi Tanabe Pharma Corp composto amina e uso farmacêutico do mesmo
EP2465492B1 (de) 2007-10-12 2015-07-01 Novartis AG Zusammensetzung mit Sphingosin-I-Phosphat (SIP)-Rezeptormodulatoren
US7816435B2 (en) * 2007-10-31 2010-10-19 Momentive Performance Materials Inc. Halo-functional silane, process for its preparation, rubber composition containing same and articles manufactured therefrom
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
DK2278960T4 (da) 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
CN103396346A (zh) * 2008-05-19 2013-11-20 杏林制药株式会社 光学活性氨基醇衍生物的制备方法
MY154685A (en) * 2008-05-20 2015-07-15 Kyorin Seiyaku Kk Agent for maintanance of induced remission
GB0901835D0 (en) 2009-02-04 2009-03-11 Syngenta Ltd Novel herbicides
GB0901834D0 (en) 2009-02-04 2009-03-11 Syngenta Ltd Novel herbicides
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
DK2452944T3 (da) 2009-07-09 2014-10-27 Kyorin Seiyaku Kk Diphenylsulfidderivater samt lægemidler indeholdende dem som aktivt stof
KR101148098B1 (ko) 2010-04-30 2012-05-22 한국화학연구원 1-[4-(4-니트로-페녹시)-페닐]-프로판-1-온을 유효성분으로 함유하는 톡소포자충 및 콕시디움에 기인한 질환의 예방 및 치료용 조성물
MX2012012926A (es) 2010-05-06 2012-12-17 Novartis Ag Tratamiento de enfermedades autoinmunes.
EA201201515A1 (ru) 2010-05-06 2013-08-30 Новартис Аг Схема приема производных диарилсульфидов
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
CN102863345A (zh) * 2011-07-06 2013-01-09 中国医学科学院药物研究所 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
EA026736B1 (ru) 2011-07-13 2017-05-31 Басф Агро Б.В. Фунгицидные замещенные 2-[2-галогеналкил-4-(фенокси)фенил]-1-[1,2,4]триазол-1-ил-этанольные соединения
US9137996B2 (en) 2011-07-15 2015-09-22 Basf Se Fungicidal alkyl- and aryl-substituted 2[-2-chloro-4-(dihalo-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds
EP2731438B1 (de) 2011-07-15 2015-04-08 Basf Se Fungizide alkyl-substituierte 2-[2-chlor-4-(4-chlor-phenoxy)-phenyl]-1-[1,2,4]triazol-1 yl-ethanolverbindungen
EP2744794B1 (de) 2011-08-15 2015-12-30 Basf Se Fungizide substituierte 1-{2-cyclyloxy-2-[2-halo-4-(4-halogen-phenoxy)-phenyl]-ethyl}-1h-[1,2,4]triazol-verbindungen
CA2842861A1 (en) 2011-08-15 2013-02-21 Basf Se Fungicidal substituted 1-{2-[2-halo-4-(4-halogen-phenoxy)-phenyl]-2-alkoxy-2-alkynyl/alkenyl-ethyl}-1h-[1,2,4]triazole compounds
EP2744791B1 (de) 2011-08-15 2015-10-28 Basf Se Fungizide substituierte 1-{2-[2-halo-4-(4-halogen-phenoxy-)phenyl-]2-alkoxy-3-methyl-butyl}-1h-[1,2,4-]triazol-verbindungen
JP6194306B2 (ja) 2012-04-23 2017-09-06 田辺三菱製薬株式会社 アミン化合物及びその医薬用途
EP2934147B1 (de) 2012-12-20 2019-11-27 BASF Agro B.V. Zusammensetzungen enthaltend eine triazol-verbindung
WO2014108286A1 (en) 2013-01-09 2014-07-17 Basf Se Process for the preparation of substituted oxiranes and triazoles
CA2916777A1 (en) 2013-07-08 2015-01-15 BASF Agro B.V. Compositions comprising a triazole compound and a biopesticide
CN104844486B (zh) * 2014-02-17 2018-10-30 中国医学科学院药物研究所 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途
EA201892682A1 (ru) 2014-06-25 2019-04-30 Басф Агро Б.В. Пестицидные композиции
EP3214937B1 (de) 2014-11-07 2024-07-03 Basf Se Pestizidgemische
US11425909B2 (en) 2016-03-16 2022-08-30 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
UA125210C2 (uk) 2016-03-16 2022-02-02 Басф Се Застосування тетразолінонів для боротьби зі стійкими фітопатогенними грибами на злакових культурах
MX2021001039A (es) 2018-07-27 2021-04-12 Priothera Ltd Preparacion para inhibir la reaparicion de una malignidad hematologica en pacientes quienes han pasado por trasplante de celulas madre hematopoyeticas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) * 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
JP3870419B2 (ja) * 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
AU735853B2 (en) 1997-04-04 2001-07-19 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compound, Pharmaceutical use thereof and synthetic intermediates therefor

Also Published As

Publication number Publication date
JP4152884B2 (ja) 2008-09-17
CA2460640A1 (en) 2003-04-10
EP1431275A1 (de) 2004-06-23
ATE463478T1 (de) 2010-04-15
US20040242654A1 (en) 2004-12-02
EP1431275B1 (de) 2010-04-07
WO2003029184A1 (en) 2003-04-10
CA2460640C (en) 2011-03-29
JPWO2003029184A1 (ja) 2005-01-13
US6963012B2 (en) 2005-11-08
EP1431275A4 (de) 2006-05-31

Similar Documents

Publication Publication Date Title
DE60235900D1 (de) Osuppressivum
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
CY1107272T1 (el) Παραγωγο διαρυλ σουλφιδιου, αλας προσθηκης εξ αυτου και ανοσοκατασταλτικο
NO20041493L (no) Kjemiske forbindelser.
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
HRP20030383B1 (hr) Laktamski spoj
DK1385514T3 (da) Spiroinden- og spiroindanforbindelser
CY1109989T1 (el) 3,4-di-υποκαθισταμενες cyclobutene-1,2-diones ως συνδετες του υποδοχεα των cxc-χημειοκινων
GB0124627D0 (en) Novel compounds
BR9804214A (pt) Compostos.
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
TR199801629A2 (xx) Fungisidal 2 -metoksibenzofenonlar.
DE60116589D1 (de) Fungizide Phenylamidinderivative
NO995963D0 (no) Karboksamider anvendelige som 5-HTIF-agonister
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
ATE250021T1 (de) Hydroxycyclopentanone
BR0206922A (pt) Compostos orgânicos
DE69912193D1 (de) Substituierte 2-Hydroxybenzophenone, ihre Herstellung, ihre Verwendung als fungizide und ihre fungizide Zusammensetzungen
DE60108209D1 (de) Fungizide Phenylimidate-Derivate
DK1328275T3 (da) Substituerede 4,5-dihydro-1,2,4-triazin-3-oner, 1,2,4-triazin-3-oner og deres anvendelse som fungicider og insekticider
BR9902096A (pt) Pitazóis.
ES2189390T3 (es) Fungicidas.
PT1234817E (pt) Processo para a preparacao de midodrina
YU83903A (sh) Farmaceutske kombinacije zasnovane na derivatima piridoindolona
DE69915688D1 (de) Benzonaphtyridin-1,8 derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition